News for Healthier Living

Novastra Launches First-in-Human Trial of Next-Generation Immune Reprogramming Cancer Therapy for Hard-to-Treat Patients

Novastra Therapeutics ("Novastra"), a Boston-founded, clinical-stage biotechnology company developing next-generation immune reprogramming therapies for cancer, today announced that its lead program, OAP-1 from its OmniAntigen(tm) XIRT platform, has entered a Phase 1b clinical study in patients with advanced solid tumors.

December 9, 2025


December 11 2025

December 10 2025

December 9 2025

December 8 2025

December 7 2025

December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025